NASDAQ : CNTX
Context Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.1891 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 17.37M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 8.62M | 7.85M | 7.22M | 7.29M | 7.79M | 3.63M |
| Research & Development | 40.11M | 31.86M | 22.70M | 17.78M | 7.09M | 3.81M |
| Operating Expenses | 48.73M | 39.70M | 29.92M | 25.07M | 14.88M | 7.44M |
| Operating Income | -48.73M | -39.70M | -29.92M | -25.07M | -14.88M | -7.44M |
| Interest Expense | -64.24K | |||||
| Interest & Investment Income | 2.46M | 3.38M | 3.20M | 1.16M | 547.27K | |
| Other Non Operating Income (Expenses) | 313.52K | 200.47K | -1.43K | -55.57K | -2.00K | 7.61K |
| EBT Excluding Unusual Items | -45.96M | -36.12M | -26.73M | -23.96M | -14.34M | -7.49M |
| Other Unusual Items | 125.58K | |||||
| Pretax Income | -45.96M | -36.12M | -26.73M | -23.96M | -14.84M | -10.46M |
| Net Income | -45.96M | -36.12M | -26.73M | -23.96M | -14.84M | -10.46M |
| Net Income to Common | -45.96M | -36.12M | -26.73M | -23.96M | -14.84M | -10.46M |
| Shares Outstanding (Basic) | 95.18M | 95.19M | 58.42M | 15.97M | 15.97M | 2.83M |
| Shares Outstanding (Diluted) | 95.18M | 95.19M | 58.42M | 15.97M | 15.97M | 2.83M |
| EPS (Basic) | -0.48 | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 |
| EPS (Diluted) | -0.48 | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 |
| Free Cash Flow | -34.03M | -26.42M | -14.56M | -21.05M | -13.59M | -8.80M |
| Free Cash Flow Per Share | -0.36 | -0.28 | -0.25 | -1.32 | -0.85 | -3.10 |
| EBITDA | -48.71M | -39.69M | -29.91M | -25.06M | -14.87M | |
| D&A For EBITDA | 19.46K | 16.25K | 10.88K | 12.04K | 9.27K | |
| EBIT | -48.73M | -39.70M | -29.92M | -25.07M | -14.88M | -7.44M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 42.99M | 66.00M | 94.43M | 14.45M | 35.50M | 49.64M |
| Cash & Short-Term Investments | 42.99M | 66.00M | 94.43M | 14.45M | 35.50M | 49.64M |
| Prepaid Expenses | 2.63M | 2.16M | 3.27M | 1.60M | 2.36M | 1.62M |
| Other Current Assets | 200.00K | 200.00K | 200.00K | |||
| Total Current Assets | 45.82M | 68.35M | 97.90M | 16.05M | 37.85M | 51.26M |
| Property, Plant & Equipment | 315.29K | 140.07K | 230.78K | 15.52K | 79.53K | |
| Other Long-Term Assets | 32.75K | 50.39K | ||||
| Total Assets | 46.13M | 68.49M | 98.13M | 16.06M | 37.97M | 51.31M |
| Accounts Payable | 3.29M | 2.53M | 1.45M | 2.38M | 936.33K | 1.83M |
| Accrued Expenses | 4.41M | 5.34M | 1.14M | 1.80M | 2.13M | 1.12M |
| Current Portion of Leases | 167.47K | 112.06K | 107.32K | 55.08K | ||
| Other Current Liabilities | 21.42K | 38.97K | 49.78K | 8.49K | 83.46K | 85.53K |
| Total Current Liabilities | 7.88M | 8.02M | 2.75M | 4.19M | 3.21M | 3.03M |
| Long-Term Leases | 77.52K | 112.06K | ||||
| Total Liabilities | 7.96M | 8.02M | 2.86M | 4.19M | 3.21M | 3.03M |
| Common Stock | 91.88K | 91.88K | 89.70K | 15.97K | 15.97K | 15.97K |
| Additional Paid-In Capital | 192.22M | 191.29M | 189.96M | 79.91M | 78.83M | 77.51M |
| Retained Earnings | -154.14M | -130.90M | -94.78M | -68.05M | -44.09M | -29.25M |
| Total Common Equity | 38.17M | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M |
| Shareholders' Equity | 38.17M | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M |
| Total Liabilities & Equity | 46.13M | 68.49M | 98.13M | 16.06M | 37.97M | 51.31M |
| Total Debt | 244.99K | 112.06K | 219.38K | 55.08K | ||
| Net Cash (Debt) | 42.75M | 65.88M | 94.21M | 14.45M | 35.44M | 49.64M |
| Net Cash Per Share | 0.45 | 0.69 | 1.61 | 0.91 | 2.22 | 17.52 |
| Filing Date Shares Outstanding | 91.88M | 91.88M | 89.70M | 15.97M | 15.97M | 15.97M |
| Total Common Shares Outstanding | 91.88M | 91.88M | 89.70M | 15.97M | 15.97M | 15.97M |
| Working Capital | 37.93M | 60.33M | 95.15M | 11.86M | 34.65M | 48.22M |
| Book Value Per Share | 0.42 | 0.66 | 1.06 | 0.74 | 2.18 | 3.02 |
| Tangible Book Value | 38.17M | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M |
| Tangible Book Value Per Share | 0.42 | 0.66 | 1.06 | 0.74 | 2.18 | 3.02 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -45.96M | -36.12M | -26.73M | -23.96M | -14.84M | -10.46M |
| Depreciation & Amortization | 19.46K | 16.25K | 10.88K | 12.04K | 9.27K | |
| Asset Writedown & Restructuring Costs | 8.50M | 2.00M | 14.75M | 578.52K | 3.09M | |
| Stock-Based Compensation | 1.59M | 1.33M | 841.87K | 1.08M | 976.44K | 511.08K |
| Other Operating Activities | 125.91K | 108.41K | 41.82K | 51.97K | 283.32K | |
| Change in Accounts Payable | 892.33K | 1.10M | -946.10K | 1.45M | -787.89K | -866.01K |
| Change in Other Net Operating Assets | 863.63K | 5.19M | -2.53M | 329.03K | 510.37K | -1.36M |
| Operating Cash Flow | -33.97M | -26.39M | -14.56M | -21.05M | -13.55M | -8.80M |
| Capital Expenditures | -55.75K | -33.95K | -7.32K | -36.84K | ||
| Sale (Purchase) of Intangibles | -6.50M | -2.00M | -14.75M | -500.00K | -250.00K | |
| Investing Cash Flow | -6.56M | -2.03M | -14.76M | -536.84K | -250.00K | |
| Issuance of Common Stock | 109.29M | 53.41M | ||||
| Other Financing Activities | -15.27K | -102.07K | ||||
| Financing Cash Flow | -15.27K | 109.29M | -102.07K | 58.39M | ||
| Net Cash Flow | -40.53M | -28.43M | 79.98M | -21.05M | -14.19M | 49.34M |
| Free Cash Flow | -34.03M | -26.42M | -14.56M | -21.05M | -13.59M | -8.80M |
| Free Cash Flow Per Share | -0.36 | -0.28 | -0.25 | -1.32 | -0.85 | -3.10 |
| Levered Free Cash Flow | -31.53M | -19.13M | -36.03M | -12.78M | -9.47M | -6.67M |
| Unlevered Free Cash Flow | -31.53M | -19.13M | -36.03M | -12.78M | -9.47M | -6.63M |
| Change in Working Capital | 1.76M | 6.28M | -3.48M | 1.78M | -277.52K | -2.22M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 17.37M | 135.06M | 94.19M | 18.04M | 10.41M | 42.46M |
| Enterprise Value | -25.37M | 58.26M | 9.63M | -3.64M | -28.94M | 63.03M |
| Last Close Price | 0.19 | 1.47 | 1.05 | 1.13 | 0.65 | 2.66 |
| PB Ratio | 0.46 | 2.23 | 0.99 | 1.52 | 0.30 | 0.88 |
| P/TBV Ratio | 0.46 | 2.23 | 0.99 | 1.52 | 0.30 | 0.88 |
| Debt / Equity Ratio | 0.01 | 0.00 | 0.00 | 0.00 | ||
| Net Debt / Equity Ratio | -1.12 | -1.09 | -0.99 | -1.22 | -1.02 | -1.03 |
| Net Debt / EBITDA Ratio | 0.88 | 1.66 | 3.15 | 0.58 | 2.38 | |
| Net Debt / FCF Ratio | 1.26 | 2.49 | 6.47 | 0.69 | 2.61 | 5.64 |
| Quick Ratio | 5.45 | 8.23 | 34.36 | 3.45 | 11.07 | 16.36 |
| Current Ratio | 5.81 | 8.52 | 35.62 | 3.83 | 11.80 | 16.90 |
| Return on Equity (ROE) | -76.14% | -46.39% | -49.89% | -102.79% | -35.74% | -53.50% |
| Return on Assets (ROA) | -45.70% | -29.79% | -32.76% | -58.01% | -20.84% | -17.96% |
| Return on Capital Employed (ROCE) | -127.40% | -65.70% | -31.40% | -211.20% | -42.80% | -15.40% |
| Earnings Yield | -255.33% | -26.75% | -28.37% | -132.83% | -142.58% | -24.62% |
| FCF Yield | -195.84% | -19.56% | -15.46% | -116.66% | -130.57% | -20.72% |
| Buyback Yield / Dilution | -7.82% | -62.94% | -265.88% | -463.44% | -37.90% |